Genelux Corporation to Participate in Upcoming Conferences

About this update from Genelux Corporation

[{"type":"image","alt":"Genelux Corporation","displaySize":"","headline":null,"caption":"Genelux Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":75,"url":"https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/PqbnzpB7NuWaPPuiKZD5BA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEwNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/555a19f80dbf3a9d98dbd557739b10ea","width":300,"height":75}},"lazy":false},{"type":"text","content":"WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences.","length":221,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.","length":286,"tagName":"p"}]},{"val":[{"type":"text","content":"TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monday, March 2, 2026, at 2:30 p.m. ET in Boston, MA.","length":238,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":524,"olType":false},{"type":"text","content":"Live webcasts of the fireside chat and presentation can be found on the Events & Presentations section of the Company’s Investor Relations website at https://investors.genelux.com/news-events/events-presentations. Following the completion of the events, an archived replay of each webcast will be available on the Company’s Investor Relations website.","length":355,"tagName":"p"},{"type":"text","content":"About Genelux Corporation","length":25,"tagName":"p"},{"type":"text","content":"Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, ope...

More updates from Genelux Corporation